Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 10

Key Takeaways: CAR T in Real-World Clinical Practice

,

Experts share their closing thoughts and key take-home messages from this discussion.

EP. 1: CAR-T in Second-Line DLBCL: When and for Whom?
EP. 2: Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
EP. 3: CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection
EP. 4: Guiding Patients Through CAR T: Key Discussion Points
EP. 5: Future Directions for CAR T-Cell Therapy in LBCL: What’s Next?
EP. 6: Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies
EP. 7: Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing
EP. 8: CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024
EP. 9: Overcoming Barriers and Improving CAR T Care in Academic and Community Settings
Now Viewing
EP. 10: Key Takeaways: CAR T in Real-World Clinical Practice

Video content above is prompted by the following:

  • Before we end, I would like to get your closing thoughts or key take-home messages.

Related Content:

Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL Video SeriesInsights
Key Messages From the Breast Cancer ADC Data Set and Closing Remarks
Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast
Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer